$6.60
3.45% today
Nasdaq, Jul 17, 10:03 pm CET
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Kura Oncology, Inc. Stock price

$6.38
-0.11 1.69% 1M
-0.80 11.14% 6M
-2.33 26.75% YTD
-16.85 72.54% 1Y
-11.78 64.87% 3Y
-11.53 64.38% 5Y
-8.62 57.47% 10Y
-8.62 57.47% 20Y
Nasdaq, Closing price Wed, Jul 16 2025
+0.25 4.08%
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Key metrics

Basic
Market capitalization
$552.4m
Enterprise Value
$-96.3m
Net debt
positive
Cash
$658.2m
Shares outstanding
80.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.1 | 4.6
EV/Sales
negative | negative
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
54.4%
Return on Equity
-42.1%
ROCE
-31.1%
ROIC
-544.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$68.0m | $121.3m
EBITDA
$-202.6m | $-238.8m
EBIT
$-203.4m | $-214.4m
Net Income
$-181.9m | $-172.9m
Free Cash Flow
$110.6m
Growth (TTM | estimate)
Revenue
- | 125.1%
EBITDA
-10.8% | -24.1%
EBIT
-10.8% | -11.0%
Net Income
-8.2% | 0.6%
Free Cash Flow
180.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-298.0% | -196.9%
EBIT
-299.2%
Net
-267.5% | -142.6%
Free Cash Flow
162.6%
More
EPS
$-2.1
FCF per Share
$1.4
Short interest
9.1%
Employees
192
Rev per Employee
$280.0k
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Kura Oncology, Inc. forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
68 68
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 82 82
42% 42%
120%
- Research and Development Expense 190 190
50% 50%
279%
-203 -203
11% 11%
-298%
- Depreciation and Amortization 0.86 0.86
1% 1%
1%
EBIT (Operating Income) EBIT -203 -203
11% 11%
-299%
Net Profit -182 -182
8% 8%
-268%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting o...
Positive
Seeking Alpha
16 days ago
Kura Oncology is a Strong Buy due to ziftomenib's positive Phase 2 data in newly diagnosed AML mutant patients and upcoming FDA Priority Review for relapsed/refractory NPM1-m/KMT2A-r AML. The pipeline is expanding beyond monotherapy, with promising results in combination regimens for newly diagnosed AML patients. Strong financials, including $703M in cash and a supportive partnership with Kyowa...
Neutral
GlobeNewsWire
about one month ago
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML –
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today